This study verified the independent and incremental value of GDF15 in identifying arteriosclerosis in OSA patients, surpassing clinical risk factors and other serum biomarkers such as AOPP and IL-6. This evidence concerns the gene GDF15 and obstructive sleep apnea syndrome.